Therapeutic Potential of Kappa-Opioids Against Cocaine - 1
Information source: National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cocaine-Related Disorders
Phase: Phase 1
Sponsored by: National Institute on Drug Abuse (NIDA)
Official(s) and/or principal investigator(s):
Sharon Walsh, Ph.D., Principal Investigator, Affiliation: Johns Hopkins University
The purpose of this study is to characterize the effects of enadoline compared to
hydromorphone and butorphanol.
Official title: Therapeutic Potential of Kappa-Opioids Against Cocaine
Study design: Primary Purpose: Screening
Minimum age: 21 Years.
Maximum age: 50 Years.
opiate experienced, healthy
physical dependence on opioids, barbiturates or alcohol
Locations and Contacts
Johns Hopkins University (BPRU) Bayview Campus, Baltimore, Maryland 21224 6823, United States
Walsh SL, Strain EC, Abreu ME, Bigelow GE. Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl). 2001 Sep;157(2):151-62.
Starting date: July 1996
Last updated: June 23, 2005